ALLO — Allogene Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $720.33m
- $271.63m
- $0.10m
- 15
- 11
- 67
- 21
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 531 | 828 | 457 | 517 | 449 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2.4 | 2.8 | 1.9 | 1.8 | 1.7 |
Prepaid Expenses | |||||
Total Current Assets | 545 | 845 | 471 | 529 | 459 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 101 | 160 | 181 | 196 | 163 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 718 | 1,228 | 1,039 | 822 | 643 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 33.1 | 94.3 | 48.2 | 53.7 | 37.1 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 88.8 | 148 | 122 | 155 | 131 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 629 | 1,080 | 916 | 667 | 512 |
Total Liabilities & Shareholders' Equity | 718 | 1,228 | 1,039 | 822 | 643 |
Total Common Shares Outstanding |